Drugs / Lorecivivint
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04598542 | Oct → Dec 2020 | — | Biosplice Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03246399 | Jul 2017 → Nov 2018 | intervertebral disk degenerative disorder | Biosplice Therapeutics, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02095548 | Mar 2014 → Sep 2015 | — | Biosplice Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 24 trials · 2 missed | ||||||
| Phase 2 | NCT03706521 | Mar 2019 → Jul 2020 | osteoarthritis, knee | Biosplice Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03727022 | Nov 2018 → Sep 2020 | osteoarthritis, knee | Biosplice Therapeutics, Inc. | Completed | Missed primary |
| Phase 2 | NCT03122860 | Apr 2017 → Apr 2018 | osteoarthritis, knee | Biosplice Therapeutics, Inc. | Completed | Mixed |
| Phase 2 | NCT02536833 | Sep 2015 → Apr 2017 | osteoarthritis | Biosplice Therapeutics, Inc. | Completed | Missed primary |
| Phase 35 trials · 2 missed | ||||||
| Phase 3 | NCT05603754 | Nov 2022 → Feb 2024 | osteoarthritis, knee | Biosplice Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04931667 | Jul → Dec 2021 | osteoarthritis, knee | Biosplice Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT04520607 | Aug 2020 → Jun 2023 | osteoarthritis, knee | Biosplice Therapeutics, Inc. | Terminated | Mixed |
| Phase 3 | NCT04385303 | May 2020 → Sep 2021 | osteoarthritis, knee | Biosplice Therapeutics, Inc. | Completed | Missed primary |
| Phase 3 | NCT03928184 | May 2019 → Aug 2021 | osteoarthritis, knee | Biosplice Therapeutics, Inc. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2021-07-22 | Biosplice Therapeutics, Inc. | Results Biosplice Publishes Phase 2B Lorecivivint Analysis Showing Clinically Meaningful Benefits to Knee Osteoarthritis Patients biosplice.com ↗
Biosplice showed that study subjects dosed with 0.07 mg lorecivivint were over two times more likely to meet the criteria for OMERACT-OARSI Strict Response, a measure that includes 50% improvement in pain or function, than those on placebo at 12 weeks. |
| 2021-04-26 | Biosplice Therapeutics, Inc. | Results Biosplice Publishes Successful Clinical Trial in Knee Osteoarthritis biosplice.com ↗
In this 24-week clinical trial, Biosplice’s groundbreaking knee OA drug candidate, lorecivivint, met primary endpoints of Pain NRS (daily pain measurement) at both 12 and 24-week timepoints. |
| 2020-05-22 | Biosplice Therapeutics, Inc. | Results Biosplice Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis biosplice.com ↗ |
All press releases naming this drug 6 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lorecivivint | “OBJECTIVE: To assess the safety and efficacy of a novel Wnt pathway modulator, lorecivivint (SM04690), for treating pain and inhibiting structural progression in moderately to...” PMID 32432388 ↗ Sep 20208“Lorecivivint (LOR; SM04690), an investigational Wnt pathway modulator” PMID 33588087 ↗ Feb 2021 |
| Known as | Adavivint | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297639 ↗ |
| Known as | LOR | “This phase 2 study was a single center, open-label study of lorecivivint (LOR) (internal identification SM04690) injected intraarticularly (IA) into the target knee (most...” NCT03706521 ↗4“This study is designed as a 3-year, multicenter, open-label study evaluating the safety, tolerability, and efficacy of intra-articular (IA) Lorecivivint (LOR) in subjects with...” NCT04931667 ↗ “Lorecivivint (LOR), a novel IA cdc2-Like Kinase (CLK)/Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase (DYRK) inhibitor thought to modulate Wnt and inflammatory pathways” PMID 37902943 ↗ Oct 2023 “Lorecivivint (LOR), an intra-articular CLK/DYRK inhibitor, modulates Wnt and inflammatory pathways.” PMID 39495154 ↗ May 2025 “Lorecivivint (LOR; SM04690), an investigational Wnt pathway modulator” PMID 33588087 ↗ Feb 2021 |
| Known as | SM04690 | “OBJECTIVE: To assess the safety and efficacy of a novel Wnt pathway modulator, lorecivivint (SM04690), for treating pain and inhibiting structural progression in moderately to...” PMID 32432388 ↗ Sep 2020 |
| Action | Inhibit | “Dual specificity tyrosine-phosphorylation-regulated kinase 1A inhibitor” CHEMBL4297639 ↗2“Dual specificity protein kinase CLK2 inhibitor” CHEMBL4297639 ↗ “a novel Wnt pathway inhibitor” PMID 28711582 ↗ Jul 2017 |
| Modality | Small molecule | “a potential OA treatment in development, lorecivivint, a novel small molecule thought to inhibit inflammation and a biological pathway called the Wnt pathway” PMID 37902943 ↗ Oct 2023 |
| Route | Other | “knee intra-articular (IA) injection” PMID 28711582 ↗ Jul 2017 |
| Target | CLK2 | “Dual specificity protein kinase CLK2 inhibitor” CHEMBL4297639 ↗ |
| Target | DYRK1A | “Dual specificity tyrosine-phosphorylation-regulated kinase 1A inhibitor” CHEMBL4297639 ↗ |